Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Oxford Immunotec Grants License over T-SPOT® technology to sanofi pasteur for human vaccine research


Oxford, UK; 04 April 2007 – Oxford Immunotec Ltd, the T cell measurement company, today announces that:

  • it has licenced its technology to sanofi pasteur, the vaccines business of the sanofi-aventis Group, which offers the broadest range of human vaccines.
  • It has settled its patent disputes with sanofi pasteur.

    Oxford Immunotec develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

    T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection. The patent licenced by sanofi pasteur covers the T-SPOT technology developed by Oxford Immunotec to measure antigen-specific effector T cells by detecting cytokine release in vitro using the ELISPOT immunoassay technique. Under the terms of the agreement, sanofi pasteur will have access to the technology under licence in its vaccine programmes. On the other hand, the parties have agreed to settle their patent disputes. Financial terms for the licence were not disclosed.

    Commenting on the successful outcome, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “We are delighted that the uncertainty caused by sanofi pasteur’s opposition to our granted patent has now been fully resolved. We continue to believe that the Company’s broad intellectual property estate is a major asset that underpins the wider value of the T-SPOT diagnostic platform, both for the Company’s first marketed product, T-SPOT.TB for diagnosing TB and in developing diagnostic products for other disease indications.”
    - ENDS -


    About Oxford Immunotec
    www.oxfordimmunotec.com
    Oxford Immunotec, the T cell measurement company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

    T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.


    About T-SPOT®.TB
    T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding $1bn. T-SPOT is a trademark of Oxford Immunotec.
    xx


    Publisher Contact Information:

    Oxford Immunotec Ltd.
    +44 (0)1235 442780
    info@oxfordimmunotec.com

    Company profile of Oxford Immunotec Ltd.
    Past press releases of Oxford Immunotec Ltd..

  • Data


    26,230
    Tech investments
    From our Online Data Service
    16,944
    VC-backed companies
    From our Radar


    Recent Deals


    DATEAMOUNTSECTOR
    Oct 11N/AInternet services
    Oct 11€1.1MKnowledge management
    Oct 11N/AInternet services
    Oct 11€13.0MBiotechnology
    Oct 11N/AMedical devices
    Oct 10€50.0MInternet services
    Oct 10€23.0MOther Computers & Electronics

    For information on Europe's most extensive database on technology funding click here!

    Events



    Press Releases


    May 28
    Identiq
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    Nethone
    nethone raised over $1 million from innovation nest

    Oct 1
    The Link App
    the link app launches version 2.0

    Mar 29
    Addex Therapeutics
    addex sucessfully raises chf40 million in capital increase

    Jan 2
    Urban Jungle
    urban jungle raises £1m in seed funding to build tech-enabled home ...





    About usContact usLegal Information
    Copyright © 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.